Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 865 2352511, +7 865 2353229.


Dependence of the severity of haloperidol catalepsy on the activity of dopaminergic and glutamatergic systems of the brain of rats with prolonged use of antipsychotics

[Experimental medicine]
Mariya Baturina; Eduard Beyer; Vladimir Baturin; Alexey Popov;

Long-term (30 days) use of haloperidol in doses of 0.1 and 0.5 mg/kg reduced the cataleptogenic effect of this antipsychotic. This was accompanied by an increase in dopamine receptors of the first type and NMDA-receptors (subunit of NMDA2A) in the forebrain tissue. Risperidone, which has a slightly different mechanism of neurotropic action, also limited the severity of catalepsy, although this effect was less pronounced and was accompanied by an increase in the number of NMDA2B subunits of NMDA receptors. The use of both drugs increased the levels of autoantibodies in the blood of animals to both dopamine and NMDA receptors. Correlation analysis revealed a positive relationship between the number of NMDA2A receptors and the intensity of the cataleptogenic effect. In contrast, high levels of autoantibodies to NMDA2A receptors coincided with a less pronounced cataleptogenic effect of haloperidol.


1. Mironov A. N., Bunyatyan N. D., Vasilev A. N. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Chast 1. M.: «Grif i K», 2012. (In Russ.).
2. Arushanyan E. B. Mechanisms of the antipsychotic effect of neuroleptics: problem state of the art. Eksperimental’naya i klinicheskaya farmakologiya. – Experimental and Clinical Pharmacology. 2008;71(5):52-57. (In Russ.) https://doi.org/10.30906/0869-2092-2008-71-5-52-57
3. Coyle J. T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology. 2006;26:363-382. https://doi.org/10.1007/s10571-006-9062-8
4. Uno Y., Coyle J. T. Glutamate hypothesis in schizophrenia. Psychiatry & Clinical Neurosciebces. 2019;73(5):204-215. https://doi.org/10.1111/pcn.12823
5. Singh S. P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25(10):859-885. https://doi.org/10.2165/11586650-000000000-00000
6. Tong J., Huang J., Luo X. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. Brain, Behavior, and Immunity. 2019;81:213-219. https://doi.org/10.1016/j.bbi.2019.06.017
7. Howes O., McCutcheon R., Stone J. Glutamate and Dopamine in Schizophrenia: An Update for the 21st Century. Psychopharmacology. 2015;29(2):97-115. https://doi.org/10.1177/0269881114563634
8. Daniel C. J. Glutamate and Schizophrenia: Phencyclidine, N-methyl-D-aspartate Receptors, and Dopamine-Glutamate Interactions. International Review of Neurobiology. 2007;78:69-108. https://doi.org/10.1016/S0074-7742(06)78003-5
9. Krzystanek M., Bogus K., Pałasz A. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacological Reports. 2015;67(5):965-969. https://doi.org/10.1016/j.pharep.2015.01.017
10. Hunt M. J., Olszewski M., Piasecka J. Effects of NMDA Receptor Antagonists and Antipsychotics on High Frequency Oscillations Recorded in the Nucleus Accumbens of Freely Moving Mice. Psychopharmacology. 2015;232(24):4525-4535. https://doi.org/10.1007/s00213-015-4073-0
11. Alfimova M. V., Golimbet V. E., Korovajceva G. I. Rol vzaimodejstviya genov NMDA- i dofaminovyh receptorov v narushenii raspoznavaniya emocional’noj mimiki pri shizofrenii. Zhurnal nevrologii i psikhiatrii imeni S. S. Korsakova. – S. S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6):47-52. (In Russ.) https://doi.org/10.17116/jnevro20171176147-52
12. Baturin V. A., Baturina M. V.,
Mamceva G. I., Boev O. I., Yarovitsky V. B., Grudina E. V. Izuchenie urovnej nejrotropnyh autoantitel u bol’nyh shizofreniej. Medicinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2016;11(2):176-178. (In Russ.) https://doi.org/10.14300/mnnc.2016.11030
13. Kelleher E., Barry H., Cotter D. R. Autoantibodies and Psychosis. Current Topics in Behavioral Neurosciences. 2020;44:85-123. https://doi.org/10.1007/7854_2019_90
14. Khandaker G. M., Dantzer R., Jones P. B. Immunopsychiatry: important facts. Psychological Medicine. 2017;47(13):2229-2237. https://doi.org/10.1017/S0033291717000745

Keywords: antipsychotics, haloperidol, risperidone, catalepsy, dopamine receptors, NMDA-receptors, autoantibodies

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy